Johnson & Johnson’s Pulmonx LUNG Stock Holding History

Johnson & Johnson’s Portfolio LUNG Stock Details LUNG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,639	Closed	-$181K	–	23
2021 Q4	$181K	Hold	5,639	–	–	0.02%	21
2021 Q3	$203K	Buy	+5,639	New	+$222K	0.02%	23

Other funds holding LUNG

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Johnson & Johnson's LUNG Position: Q1 2022 in Review

Johnson & Johnson sold out of Pulmonx (LUNG) in Q1 2022, closing a stake of 5,639 shares — an estimated $181K sold.

Johnson & Johnson first reported a position in LUNG in Q3 2021 and held it in 2 quarters. The position peaked at $203K in Q3 2021. 109 funds tracked by Wall St. Rank hold LUNG as of Q1 2022.

Johnson & Johnson reported no remaining Pulmonx position as of Q1 2022 after selling out during the quarter.
Johnson & Johnson sold 5,639 Pulmonx shares in Q1 2022, an estimated $181K.
Johnson & Johnson first reported a position in Pulmonx in Q3 2021 and held it in 2 quarters.
Johnson & Johnson's Pulmonx position peaked at $203K in Q3 2021.
109 funds tracked by Wall St. Rank held Pulmonx as of Q1 2022.

Based on Johnson & Johnson's 13F filing for Q1 2022, filed 9 May 2022.